U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula 3Na.O4P
Molecular Weight 163.9407
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SODIUM PHOSPHATE, TRIBASIC, ANHYDROUS

SMILES

[Na+].[Na+].[Na+].[O-]P([O-])([O-])=O

InChI

InChIKey=RYFMWSXOAZQYPI-UHFFFAOYSA-K
InChI=1S/3Na.H3O4P/c;;;1-5(2,3)4/h;;;(H3,1,2,3,4)/q3*+1;/p-3

HIDE SMILES / InChI

Molecular Formula O4P
Molecular Weight 94.9714
Charge -3
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula Na
Molecular Weight 22.98976928
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Phosphate is a major intracellular anion in mammals. Hydrogen phopshate is a protonated form of phosphate. In serum, phosphate exists in two forms, dihydrogen phosphate (H2PO4) and its salt, mono-hydrogen phosphate (HPO4). At the physiologic pH of 7.40, the pK of H2PO4 is 6.8 and the ratio of HPO4 to H2PO4 is 4:1. Altered level of phosphate can be an indicator of various disorders, such as chronic renal failure, hypoparathyroidism, familial intermittent hyperphosphatemia, endocrine disorders, hyperthyroidism, acromegaly, juvenile hypogonadism, etc. These disorders may lead to either hyper- or hypophosphatemia, which can be caused by cellular shifts of phosphate. Patients with hypophosphatemia can be treated with dietary phosphate supplements (potassium phosphate, for example).

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
PROCALAMINE

Approved Use

ProcalAmine is indicated for peripheral administration in adults to preserve body protein and improve nitrogen balance in well-nourished, mildly catabolic patients who require short-term parenteral nutrition.

Launch Date

1982
Palliative
Unknown

Approved Use

Unknown
Palliative
Unknown

Approved Use

Unknown
Palliative
Unknown

Approved Use

Unknown
Palliative
Unknown

Approved Use

Unknown
Diagnostic
Unknown

Approved Use

Unknown
Diagnostic
Unknown

Approved Use

Unknown
Primary
SODIUM PHOSPHATES INJECTION

Approved Use

Sodium Phosphates Injection, USP, 3mM P/mL, is indicated as a source of phosphorus, for addition to large volume intravenous fluids, to prevent or correct hypophosphatemia in patients with restricted or no oral intake. It is also useful as an additive for preparing specific intravenous fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions. The concomitant amount of sodium (4 mEq/mL) must be calculated into total electrolyte content of such prepared solutions.
PubMed

PubMed

TitleDatePubMed
Diurnal variation in the levels of glucose and related substances in healthy and diabetic subjects during starvation.
1967 Feb
Phosphorus amendment reduces hepatic and renal oxidative stress in mallards ingesting lead-contaminated sediments.
2006 Jun
Patents

Patents

Sample Use Guides

lose body protein: approximately three liters per day of ProcalAmine will provide a total of 90 grams of amino acids, 390 nonprotein calories and the recommended daily intake of principal intra- and extracellular electrolytes for the stable patient. Therapy can begin with three liters of ProcalAmine on the first day with close monitoring of the patient. As with all intravenous fluid therapy, the goal is to provide adequate water to compensate for insensible, urinary and other losses, and electrolytes for replacement and maintenance. These requirements should be determined frequently and appropriately administered. Additional electrolytes should be administered evenly throughout the day, and irritating medications should be injected at an alternate infusion site. Pediatric Use ProcalAmine is intended for use in adults. Use of ProcalAmine in pediatric patients is governed by the same considerations that affect the use of any amino acid solution in pediatrics. The amount administered is dosed on the basis of grams of amino acids/kg of body weight/day. Two to three g/kg of body weight for infants with adequate calories are generally sufficient to satisfy protein needs and promote positive nitrogen balance. Solutions administered by peripheral vein should not exceed twice normal serum osmolarity (718 mOsmol/L). Venous irritation at an infusion site can be minimized by the selection of a large peripheral vein as well as by slowing the rate of infusion. In pediatric patients, the final solution should not exceed twice normal serum osmolarity (718 mOsmol/L). nausea: for maximum effectiveness never dilute or drink fluids of any kind immediately before or after taking this product. Adults and children 12 years of age and over: one or two tablespoons; children 2 to under 12: one or two teaspoons; repeat dose every 15 minutes or until distress subsides; do not take more than 5 doses in 1 hour without consulting a doctor.
Route of Administration: Other
37% phosphoric acid, 17% EDTA, 10% citric acid, 2% chlorhexidine (solution and gel), and 5.25% NaOCl were tested their antimicrobial activity was tested against Candida albicans, Staphylococcus aureus, Enterococcus faecalis, Escherichia coli, Actinomyces meyeri, Parvimonas micra, Porphyromonas gingivalis, and Prevotella nigrescens according to the agar diffusion method. The cytotoxicity of the irrigants was determined by using the MTT assay. Phosphoric acid presented higher antimicrobial activity compared to the other tested irrigants.
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:15:34 GMT 2025
Edited
by admin
on Mon Mar 31 18:15:34 GMT 2025
Record UNII
SX01TZO3QZ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SODIUM PHOSPHATE, TRIBASIC, ANHYDROUS
II  
Common Name English
SODIUM PHOSPHATE TRIBASIC
WHO-DD  
Preferred Name English
SODIUM PHOSPHATE, TRIBASIC, ANHYDROUS [II]
Common Name English
SODIUM PHOSPHATE, TRIBASIC ANHYDROUS
Common Name English
SODIUM PHOSPHATE (TRIBASIC)
Common Name English
TRIBASIC SODIUM-PHOSPHATE
Common Name English
E-339(III)
Code English
Sodium phosphate tribasic [WHO-DD]
Common Name English
INS-339(III)
Code English
Sodium orthophosphate
Common Name English
INS NO.339(III)
Code English
TRISODIUM ORTHOPHOSPHATE
Common Name English
NSC-215202
Code English
SODIUM PHOSPHATE, TRIBASIC [MI]
Common Name English
SODIUM PHOSPHATE,TRIBASIC [VANDF]
Common Name English
PHOSPHORIC ACID, SODIUM SALT (1:3)
Systematic Name English
TRISODIUM PHOSPHATE [HSDB]
Common Name English
Classification Tree Code System Code
CODEX ALIMENTARIUS (GSFA) INS-339(III)
Created by admin on Mon Mar 31 18:15:34 GMT 2025 , Edited by admin on Mon Mar 31 18:15:34 GMT 2025
JECFA EVALUATION INS-339(III)
Created by admin on Mon Mar 31 18:15:34 GMT 2025 , Edited by admin on Mon Mar 31 18:15:34 GMT 2025
NCI_THESAURUS C29730
Created by admin on Mon Mar 31 18:15:34 GMT 2025 , Edited by admin on Mon Mar 31 18:15:34 GMT 2025
EPA PESTICIDE CODE 76406
Created by admin on Mon Mar 31 18:15:34 GMT 2025 , Edited by admin on Mon Mar 31 18:15:34 GMT 2025
Code System Code Type Description
NCI_THESAURUS
C66552
Created by admin on Mon Mar 31 18:15:34 GMT 2025 , Edited by admin on Mon Mar 31 18:15:34 GMT 2025
PRIMARY
MERCK INDEX
m10062
Created by admin on Mon Mar 31 18:15:34 GMT 2025 , Edited by admin on Mon Mar 31 18:15:34 GMT 2025
PRIMARY Merck Index
RXCUI
1307158
Created by admin on Mon Mar 31 18:15:34 GMT 2025 , Edited by admin on Mon Mar 31 18:15:34 GMT 2025
PRIMARY RxNorm
FDA UNII
SX01TZO3QZ
Created by admin on Mon Mar 31 18:15:34 GMT 2025 , Edited by admin on Mon Mar 31 18:15:34 GMT 2025
PRIMARY
ECHA (EC/EINECS)
231-509-8
Created by admin on Mon Mar 31 18:15:34 GMT 2025 , Edited by admin on Mon Mar 31 18:15:34 GMT 2025
PRIMARY
DAILYMED
SX01TZO3QZ
Created by admin on Mon Mar 31 18:15:34 GMT 2025 , Edited by admin on Mon Mar 31 18:15:34 GMT 2025
PRIMARY
SMS_ID
100000126044
Created by admin on Mon Mar 31 18:15:34 GMT 2025 , Edited by admin on Mon Mar 31 18:15:34 GMT 2025
PRIMARY
PUBCHEM
24243
Created by admin on Mon Mar 31 18:15:34 GMT 2025 , Edited by admin on Mon Mar 31 18:15:34 GMT 2025
PRIMARY
EVMPD
SUB32967
Created by admin on Mon Mar 31 18:15:34 GMT 2025 , Edited by admin on Mon Mar 31 18:15:34 GMT 2025
PRIMARY
CAS
7601-54-9
Created by admin on Mon Mar 31 18:15:34 GMT 2025 , Edited by admin on Mon Mar 31 18:15:34 GMT 2025
PRIMARY
NSC
215202
Created by admin on Mon Mar 31 18:15:34 GMT 2025 , Edited by admin on Mon Mar 31 18:15:34 GMT 2025
PRIMARY
HSDB
583
Created by admin on Mon Mar 31 18:15:34 GMT 2025 , Edited by admin on Mon Mar 31 18:15:34 GMT 2025
PRIMARY
EPA CompTox
DTXSID2035223
Created by admin on Mon Mar 31 18:15:34 GMT 2025 , Edited by admin on Mon Mar 31 18:15:34 GMT 2025
PRIMARY
Related Record Type Details
SOLVATE->ANHYDROUS
SOLVATE->ANHYDROUS